IGI’s new drug candidate ISB 2301 to target solid tumors

The company intends to file an IND submission by the end of this year and begin clinical studies in 2027

MedGenome to expand integrated diagnostics access across Mumbai suburbs

Collaboration with Siddhi Diagnostics combines genomics and advanced imaging capabilities to strengthen precision diagnostics in high-growth suburban markets

Merck reports breakthrough Phase 3 win for sac-TMT in endometrial cancer

Merck to showcase 100+ oncology studies at 2026 ASCO meeting

Highlighting KEYTRUDA & expanding cancer pipeline

Actio Biosciences launches Phase 1b/2 trial for ultra-rare pediatric epilepsy therapy

The company also confirmed that ABS-1230 has been accepted into the U.S. Food and Drug Administration’s Rare Disease Evidence Principles (RDEP) process

GRIN Therapeutics launches Phase 3 beeline study in Europe for radiprodil in GRIN-NDD

This is an exciting and meaningful milestone for GRIN Therapeutics

Eli Lilly unveils $4.5 bn Indiana expansion

The investment will upgrade and expand production capabilities at Lilly Lebanon API and Lilly Lebanon Advanced Therapies

SetPoint Medical launches first-in-human MS pilot study using implanted nerve stimulation device

Alkem Laboratories receives 7 observations following US FDA inspection at Daman facility

The US regulator conducted an inspection at the Amaliya manufacturing plant between April 20 and May 1, 2026

Gilead completes $7.8B Arcellx acquisition & takes full control of Myeloma CAR-T candidate

Under the terms, Arcellx shareholders received $115 per share in cash plus a non-transferable contingent value right